 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 February 2003 | Volume 138 Issue 3 | Pages 215-229
Background: Type 2 diabetes mellitus is associated with a heavy burden of suffering. Screening for diabetes is controversial.
Purpose: To examine the evidence that screening and earlier treatment are effective in reducing morbidity and mortality associated with diabetes.
Data Sources: MEDLINE, the Cochrane Library, reviews, and experts, all of which addressed key questions about screening.
Study Selection: Studies that provided information about the existence and length of an asymptomatic phase of diabetes; studies that addressed the accuracy and reliability of screening tests; and randomized, controlled trials with health outcomes for various treatment strategies were selected.
Data Extraction: Two reviewers abstracted relevant information using standardized abstraction forms and graded articles according to U.S. Preventive Services Task Force criteria.
Data Synthesis: No randomized, controlled trial of screening for diabetes has been performed. Type 2 diabetes mellitus includes an asymptomatic preclinical phase; the length of this phase is unknown. Screening tests can detect diabetes in its preclinical phase. Over the 10 to 15 years after clinical diagnosis, tight glycemic control probably reduces the risk for blindness and end-stage renal disease, and aggressive control of hypertension, lipid therapy, and aspirin use reduce cardiovascular events. The magnitude of the benefit is larger for cardiovascular risk reduction than for tight glycemic control. The additional benefit of starting these treatments in the preclinical phase, after detection by screening, is uncertain but is probably also greater for cardiovascular risk reduction.
Conclusions: The interventions that are most clearly beneficial during the preclinical phase are those that affect the risk for cardiovascular disease. The magnitude of additional benefit of initiating tight glycemic control during the preclinical phase is uncertain but probably small.
Author and Article Information
From University of North Carolina at Chapel Hill, Chapel Hill, and Research Triangle Institute, Research Triangle Park, North Carolina; Yale University Medical School, New Haven, Connecticut; Tri-County Family Medicine, Cohocton, New York; and Virginia Commonwealth University, Fairfax, Virginia.
Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the U.S. Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Grant Support: This study was conducted by the Research Triangle Institute–University of North Carolina Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality, Rockville, Maryland (contract no. 290-97-0011, task order 3).
Requests for Single Reprints: Reprints are available from the Agency for Healthcare Research and Quality Web site (http://www.ahrq.gov/clinic/uspstfix.htm) or the Agency for Healthcare Research and Quality Publications Clearinghouse.
Current Author Addresses: Dr. Harris: Sheps Center for Health Services Research, 725 Airport Road, CB # 7590, Chapel Hill, NC 27599-2949.
Dr. Donahue: University of North Carolina, CB #7595 Manning, Chapel Hill, NC 27599.
Dr. Rathore: Yale University School of Medicine, PO Box 208025, New Haven, CT 06520-8025.
Dr. Frame: Tri-County Family Medicine, Box 112, Cohocton, NY 14826.
Dr. Woolf: Virginia Commonwealth University, 3712 Charles Stewart Drive, Fairfax, VA 22033.
Dr. Lohr: Research Triangle Institute, 3040 Cornwallis Road, Research Triangle Park, NC 27709. CLINICAL GUIDELINES
Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  U.S. Preventive Services Task Force Screening for Type 2 Diabetes Mellitus in Adults: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med, June 3, 2008; 148(11): 846 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Norris, D. Kansagara, C. Bougatsos, and R. Fu Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, June 3, 2008; 148(11): 855 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Finucane Intensive Glucose Control in Elderly Adults JAMA, May 23, 2007; 297(20): 2195 - 2196. [Full Text] [PDF]
|
|
|
|
|
|
L. E. Boulware, S. Marinopoulos, K. A. Phillips, C. W. Hwang, K. Maynor, D. Merenstein, R. F. Wilson, G. J. Barnes, E. B. Bass, N. R. Powe, et al. Systematic Review: The Value of the Periodic Health Evaluation Ann Intern Med, February 20, 2007; 146(4): 289 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2007 Diabetes Care, January 1, 2007; 30(suppl_1): S4 - S41. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Koopman, A. G. Mainous III, H. A. Liszka, J. A. Colwell, E. H. Slate, M. A. Carnemolla, and C. J. Everett Evidence of Nephropathy and Peripheral Neuropathy in US Adults With Undiagnosed Diabetes. Ann. Fam. Med, September 1, 2006; 4(5): 427 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Finucane The Dogma of "Tight Control": Beyond the Limits of Evidence. Arch Intern Med, August 14, 2006; 166(15): 1671 - 1672. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Durso Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA, April 26, 2006; 295(16): 1935 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. O'Connor, E. Gregg, W. A. Rush, L. M. Cherney, M. N. Stiffman, and M. M. Engelgau Diabetes: How Are We Diagnosing and Initially Managing It? Ann. Fam. Med, January 1, 2006; 4(1): 15 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes-2006 Diabetes Care, January 1, 2006; 29(suppl_1): S4 - S42. [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Feig, V. A. Palda, L. Lipscombe, and with The Canadian Task Force on Preventive Health Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care Can. Med. Assoc. J., January 18, 2005; 172(2): 177 - 180. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Koopman, A. G. Mainous III, V. A. Diaz, and M. E. Geesey Changes in Age at Diagnosis of Type 2 Diabetes Mellitus in the United States, 1988 to 2000 Ann. Fam. Med, January 1, 2005; 3(1): 60 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes Diabetes Care, January 1, 2005; 28(suppl_1): S4 - S36. [Full Text] [PDF]
|
|
|
|
|
|
T. E. Finucane Translating "Tight Control"? Ann Intern Med, November 16, 2004; 141(10): 822 - 822. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Engelgau, L. S. Geiss, D. Murphy, K M. Venkat Narayan, and F. Vinicor Translating "Tight Control"? Ann Intern Med, November 16, 2004; 141(10): 822 - 823. [Full Text] [PDF]
|
|
|
|
 |
|
 USPSTF: Screening for Type 2 Diabetes in Adults Journal Watch Women's Health, April 23, 2003; 2003(423): 5 - 5. [Full Text]
|
|
|
|
 |
|
 Screening for Type 2 Diabetes in Adolescents Journal Watch Pediatrics and Adolescent Medicine, February 24, 2003; 2003(224): 5 - 5. [Full Text]
|
|
|
|
 |
|
 Diabetes Mellitus: Insufficient Evidence for Screening People at Average Risk Journal Watch (General), February 14, 2003; 2003(214): 3 - 3. [Full Text]
|
|
Article
